Two or more recorded comorbidities were associated with a nearly four-fold increase. There was a significant decrease in odds associated with surgery (OR 0.29, 95% CI 0.24 to 0.35). Independently of disease severity and comorbidities, women over 70 were less likely than those under 50 to be treated surgically and this was even more pronounced in those aged over 80 (OR 0.09, 95% CI 0.07 to 0.10).
ARTICLE FOCUS
• Several studies have shown that the UK has lower survival for breast cancer than some other
European countries with a similar expenditure on health care.
• Differences have been shown to occur mainly in older patients and in the first year after diagnosis.
• Several reasons/explanations have been proposed.
KEY MESSAGES
• This study shows that breast cancer patients dying in the first year after diagnosis are more likely to be older, have more advanced disease and existing comorbidities.
• Surgical treatment and (to a lesser extent) radiotherapy and tamoxifen usage were associated with a reduced risk of early death.
• The likelihood of receiving surgery was inversely related to age, independently of comorbidity and disease severity.
• These findings suggest that early detection, management of comorbidities and optimization of treatment of older patients are important target areas to improve outcomes.
STRENGTHS AND LIMITATIONS
• This is a large cohort of women diagnosed with breast cancer and the results may be generalisable to women treated for breast cancer in the UK during the same time period.
• Many variables that may be related to both risk factors and outcomes have not been assessed in this study. However, their correlation with death within a year would have to be very strong to explain the strong associations seen in our data. 
Introduction
Despite the decline in breast cancer mortality rates seen in the UK since the late 1980s, survival rates are still substantially lower than in many other European countries. 1;2 It has been difficult to pinpoint the reasons for these differences. Beral and Peto 3 have suggested that they may be due to bias relating to artefacts in cancer registration rather than to genuine differences in diagnosis and management of breast cancer. However, a recent study by Møller et al 4 has shown that such effects are unlikely to make a significant contribution to observed differences in survival. The effects of incomplete ascertainment and registration from death certificates only on survival comparisons based on cancer registry data have been investigated in detail by Robinson et al. 5 One important observation in some studies remains unexplained, namely that of poorer survival in UK patients soon after their diagnosis. Sant et al 6 demonstrated a higher risk of death in women with breast cancer in the UK in the first six months after diagnosis than in other European countries. This was particularly pronounced for the youngest (under 29 years) and oldest (over 80 years) age groups.
Six months from diagnosis, survival patterns in the UK became more similar to those in the other
European countries. Further analysis of the survival differential has revealed that disparities between the UK and northern European countries (Sweden and Norway) occur mainly for older women in the first year after diagnosis. 7 Eighty-one percent of the excess UK deaths occur within two years of diagnosis.
The aim of this study was to investigate factors associated with early mortality (within one year following diagnosis) in a sample of UK women diagnosed with breast cancer during 1996-2005. Since surgical intervention with a curative intent is strongly related to reduced mortality, a secondary aim of the study was to identify the patient characteristics most often associated with the failure to use this treatment option.
Subjects and methods
We conducted a cohort study using data from the North Thames Prospective Audit of Breast Cancer, Data on different treatment modes (surgery, radiotherapy, chemotherapy and tamoxifen) were taken from the Audit database, augmented by information from the TCR database where possible. Cases were matched to Hospital Episode Statistics (HES) data using name, NHS number, date of birth, and date of diagnosis within 90 days of that recorded in the audit database in order to obtain further information on receipt of surgery. Women with a C50 diagnosis (breast cancer) and a B or T8 code in the HES surgery field were regarded as having had surgery. Only 98 cases were re-coded on this basis, illustrating the completeness of the audit database in this respect.
Cause of death was available from the TCR database for 85% of the women who died during the study period. A categorical variable accounting for calendar period of diagnosis was included to adjust for diagnosis and treatment in relation to the implementation of the Cancer Plan. As per the methodology of Rachet et al Clinical, demographic, pathological and treatment-related factors were compared between women who died from any cause within one year of their diagnosis and those who survived beyond this year.
Univariate analyses were performed using chi 2 tests and unadjusted (bivariate) logistic regression models. A multivariate logistic regression model investigated the independent contribution of all covariates. This model included surgery but not collinear covariates, i.e. variables that were only known for patients who had surgery, namely tumour size and node status.
The regression models assessed the effects of age, ethnicity, mode of presentation (screening, symptoms or incidental), distant metastases at diagnosis, comorbidities, period of diagnosis and treatments (surgery, radiotherapy, tamoxifen and chemotherapy) on early death from any cause. The Additional logistic regression models were used to determine which factors were associated with use of surgery. All analyses were conducted using STATA 10.
Results
The study population consisted of 15,037 women of whom 4,456 (30%) were over 70 years old at the time of their diagnosis. The majority of women (78%) presented symptomatically, and 82% of those with known ethnicity were recorded as white. Over a mean follow up of 5.6 years there were 4,765 deaths. Table 1 shows the underlying cause of death in these women. 980 women (6.5% of the total)
died within a year of their diagnosis, and of these 464 women were known to have died from breast cancer. Amongst those for whom the cause of death was known, there was no significant difference in the proportions dying from different causes between those who died within or after the first year since diagnosis (chi 2 = 10.6; 9 df; p = 0.30). However, significantly more of the women who died early had an unrecorded cause of death (26% versus 12%). Table 2 describes the characteristics of women who survived one year beyond diagnosis and those who did not, and Table 3 shows the results of the logistic regression analyses. In univariate analyses (chi 2 values in Table 2 and unadjusted odds ratios in Surgical treatment was associated with highly significantly reduced odds of early death from any cause (OR 0.12, 95% CI 0.11 to 0.14), as was treatment with chemotherapy (OR 0.60, 95% CI 0.51 to 0.71) and radiotherapy (OR 0.27, 95% CI 0.23 to 0.32). There was no significant association between tamoxifen usage and early death (OR 0.94, 95% CI 0.79 to 1.12). The time period in which women were diagnosed (before, during or after implementation of the Cancer Plan) was not significantly associated with death within a year of diagnosis in univariate models (chi 2 = 3.54; p = 0.17).
The results of the multivariate logistic regression analysis to assess the factors independently associated with early death are shown as the adjusted odds ratios in Overall, 13.3% of women did not have surgery as part of their treatment (Table 2) , and this proportion was significantly greater in women who died within a year of diagnosis (50% vs. 11%). The characteristics of women who did or did not receive surgical treatment are shown in Table 4 . Those receiving surgery were significantly younger, and were more likely to present via screening, to be free of metastases at diagnosis and to have fewer comorbidities. For those of known ethnicity, there was no difference in the proportions receiving surgery between white and non-white women. However, the proportion of cases with unknown ethnicity was significantly greater in those not receiving surgery (38.7% versus 23.8%).
In multivariate analysis (Table 5) , mode of presentation, older age (particularly > 80 years), distant metastases on presentation and comorbidities were independent predictors of no surgical treatment 
Discussion
This study in more than 15,000 women diagnosed with breast cancer in the North Thames area found that age and disease severity at diagnosis were independent predictors of early death from any cause. In the women analysed here, distant metastases on diagnosis were a strong predictor of early death, increasing the odds of dying within a year of diagnosis more than eight-fold (OR 8.41, 95% CI 6.49 to 10.89). This effect was independent of age, comorbidities and treatment. Surgery was strongly associated with a reduced risk of early death, and older patients were less likely to receive surgery.
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Another potential limitation of this study is missing information. Women with missing data on ethnicity, presentation and distant metastases were more likely to die within a year of their diagnosis and were less likely to receive surgical treatment. They may represent women who were seriously ill at diagnosis and who were not scheduled for surgery. An analysis of the characteristics of patients with several missing data elements suggests that these women tend to be older, have more severe disease (as determined by a proxy of tumour size) and are more likely to die early. A failure to record important details relating to their diagnosis and treatment may be a reflection of the care they receive.
With respect to this study, if women with missing information have worse disease and are generally older, then the estimates of association between these variables and early death will be biased towards underestimates of the true effects. 28 concluded that the audit database was a reasonably reliable source of such data.
The effects of deprivation on disease severity and ultimately on mortality were not explored in this study. Such analyses rely on potential patient identifiers such as postcode data that were not available to us. Deprivation has been linked to poorer patient outcomes for UK breast cancer patients in several studies 10;29-31 and stated aims of the Cancer Plan and the Cancer Reform Strategy [32] [33] [34] are to tackle the inequalities in cancer survival between different socioeconomic groups in England.
Conclusions
Our findings offer more detailed insights into the determinants of death in the first year after a diagnosis of breast cancer, a period shown to be important in international comparisons. As expected, early death is linked to older age and to the presence of comorbidities. Comorbidities can be addressed in the long run through general health policy, but two other determinants of early death identified by this study are potential avenues for intervention.
Firstly, the findings relating to disease severity lend empirical support to the notion that late diagnosis is a major determinant of early death. This supports the rationale for projects that focus on increasing awareness of breast symptoms and the importance of screening. Secondly, surgery is independently associated with a large reduction in the risk of early death, and older women were -independently of disease severity and comorbidity -much less likely to receive surgery. Assuming surgery is an indicator of attempts at curative treatment, there may be benefits of increased treatment activity for older women. 
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Data sharing
No additional data available. Two or more recorded comorbidities were associated with a nearly four-fold increase. There was a significant decrease in odds associated with surgery (OR 0.29, 95% CI 0.24 to 0.35). Independently of disease severity and comorbidities, women over 70 were less likely than those under 50 to be treated surgically and this was even more pronounced in those aged over 80 (OR 0.09, 95% CI 0.07 to 0.10).
Other factors independently associated with a reduced likelihood of surgery included a non-screening presentation, non-white ethnicity and additional comorbidities. Conclusions: These findings may partially explain the survival discrepancies between the UK and other European countries in female breast cancer patients. The study identifies a group of women with a particularly poor prognosis for whom interventions aiming at early detection may be targeted. 
ARTICLE FOCUS
• Several studies have shown that the UK has lower survival for breast cancer than some other European countries with a similar expenditure on health care.
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STRENGTHS AND LIMITATIONS
• Many variables that may be related to both risk factors and outcomes have not been assessed in this study. However, their correlation with death within a year would have to be very strong to explain the strong associations seen in our data. occur mainly for older women in the first year after diagnosis. 4 Eighty-one percent of the excess UK deaths occur within two years of diagnosis.
Beral and Peto 5 have suggested that observed differences in survival may be due to bias relating to artefacts in cancer registration rather than to genuine differences in diagnosis and management of breast cancer. However, a recent study by Møller et al 6 has shown that such effects are unlikely to make a significant contribution to observed differences in survival. The effects of incomplete ascertainment and registration from death certificates only on survival comparisons based on cancer registry data have been investigated in detail by Robinson et al. 7 The aim of this study was to investigate factors associated with early mortality (within one year following diagnosis) in a sample of UK women diagnosed with breast cancer during 1996-2005. Since surgical intervention with a curative intent is strongly related to reduced mortality, a secondary aim of the study was to identify the patient characteristics most often associated with the failure to use this treatment option.
Subjects and methods
We conducted a cohort study using data from the North Thames Prospective Audit of Breast Cancer, patients. This is a weighted index based on the number and severity of 17 potential serious comorbid conditions that affect mortality. 9 The index was categorised into the groups 0,1 and 2+.
Clinical, demographic, pathological and treatment-related factors were compared between women who died from any cause within one year of their diagnosis and those who survived beyond this year.
All cause mortality, rather than death from breast cancer, was used partly because specific cause of death was not known in 15% of the women, but also because the international study 4 which highlighted the adverse survival in English women in the first year post diagnosis was also based on The regression models assessed the effects of age, ethnicity, mode of presentation (screening, symptoms or incidental), distant metastases at diagnosis, comorbidities, period of diagnosis and treatments (surgery, radiotherapy, tamoxifen and chemotherapy) on early death from any cause. The results are presented as odds ratios (ORs), both unadjusted (univariate) and fully adjusted (multivariate), with 95% confidence intervals (CIs).
Additional logistic regression models were used to determine which factors were associated with use of surgery. All analyses were conducted using STATA 10.
Results
The study population consisted of 15,037 women of whom 4,456 (30%) were over 70 years old at the time of their diagnosis. The majority of women (78%) presented symptomatically, and 82% of those with known ethnicity were recorded as white. Over a mean follow up of 5.6 years there were 4,765 deaths. Table 1 shows the underlying cause of death in these women. 980 women (6.5% of the total cohort and 20.6% of all deaths) died within a year of their diagnosis, and of these 464 women were known to have died from breast cancer. Amongst those for whom the cause of death was known, there was no significant difference in the proportions dying from different causes between those who died within or after the first year since diagnosis (chi 2 = 10.6; 9 df; p = 0.30). However, significantly more of the women who died early had an unrecorded cause of death (26% versus 12%). Table 2 describes the characteristics of women who survived one year beyond diagnosis and those who did not, and Table 3 shows the results of the logistic regression analyses. In univariate analyses (chi 2 values in Table 2 and unadjusted odds ratios in Table 3 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 The results of the multivariate logistic regression analysis to assess the factors independently associated with early death are shown as the adjusted odds ratios in Table 3 Overall, 13.3% of women did not have surgery as part of their treatment (Table 2) , and this proportion was significantly greater in women who died within a year of diagnosis (50% vs. 11%). The characteristics of women who did or did not receive surgical treatment are shown in Table 4 . Those receiving surgery were significantly younger, and were more likely to present via screening, to be free of metastases at diagnosis and to have fewer comorbidities. For those of known ethnicity, there was no difference in the proportions receiving surgery between white and non-white women. However, the proportion of cases with unknown ethnicity was significantly greater in those not receiving surgery (38.7% versus 23.8%).
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Discussion
Poorer prognosis of older women with breast cancer has been attributed variously to treatment received, 10-17 more severe disease on presentation 13;18-21 and to the presence of comorbidities. 10 Stage was identified as the most important factor explaining breast cancer survival discrepancies between European countries for women diagnosed between 1990 and 1992, 19 particularly in older age groups.
This study in more than 15,000 women diagnosed with breast cancer in the North Thames area found that age and disease severity at diagnosis were independent predictors of early death from any cause. In the women analysed here, distant metastases on diagnosis were a strong predictor of early death, increasing the odds of dying within a year of diagnosis more than eight-fold (OR 8.41, 95% CI 6.49 to 10.89). This effect was independent of age and treatment. It was also independent of patient comorbidities, although this should be interpreted with some caution as comorbidity data were available only for the 60% of participants who could be successfully linked to the HES dataset.
Surgery was strongly associated with a reduced risk of early death, and older patients were less likely to receive surgery. While women of white ethnicity were at greater odds of early death in univariate analyses, this association was no longer significant when the model was adjusted for the other covariates. The white women were in general older than the non-white women, and this may explain these findings.
However, in the adjusted analysis, white women were more likely to be treated surgically than those belonging to non-white ethnic groups. These results should perhaps be treated with caution, given the large proportion (26%) of cases for which ethnicity was not known.
Radiotherapy and tamoxifen treatments were independently associated with reduced likelihood of early death, while chemotherapy was associated with increased odds of dying within a year of 23 This group is likely to have a particularly poor prognosis. Nearly 40% of women who died early in our study were aged over 80 years and 66% (252/383) of them had not had surgery.
In our study, age was strongly inversely associated with the likelihood of receiving surgery. This reflects the well described pattern in other studies that older women are less likely to receive treatment than younger women. Patient comorbidity has been shown to be a potentially important confounder in studies of treatment received, 15;25 but our analyses suggest that older women are less likely to receive surgery even after adjusting for comorbidities. Comorbidity data were missing for approximately 40% of participants.
Patients with missing comorbidity data were less likely to receive surgery although there was no association between these missing data and early death after adjustment for other factors.
One potential limitation of this study is missing information. Women with missing data on ethnicity, presentation and distant metastases were more likely to die within a year of their diagnosis and were less likely to receive surgical treatment. They may represent women who were seriously ill at diagnosis and who were not scheduled for surgery. An analysis of the characteristics of patients with several missing data elements suggests that these women tend to be older, have more severe disease (as determined by a proxy of tumour size) and are more likely to die early. Additionally, a failure to record important details relating to their diagnosis and treatment may be an indication that such patients are receiving worse care. With respect to this study, if women with missing information have worse disease and are generally older, then the estimates of association between these variables and early death will be biased towards underestimates of the true effects. Retrospective analyses rely on records in which some information may be inaccurate. In this study a particular effort was made to ensure that the surgical status of women was recorded correctly as this was considered an important marker of the quality of treatment and was expected to be strongly associated with outcome. Time and resource constraints precluded this additional effort being extended to other variables to verify database entries. However, an earlier study looking at trends in the treatment of breast cancer, 26 concluded that the audit database was a reasonably reliable source of such data.
The effects of deprivation on disease severity and ultimately on mortality were not explored in this study. Such analyses rely on potential patient identifiers such as postcode data that were not available to us. Deprivation has been linked to poorer patient outcomes for UK breast cancer patients in several studies 22;27-29 and stated aims of the Cancer Plan and the Cancer Reform Strategy [30] [31] [32] are to tackle the inequalities in cancer survival between different socioeconomic groups in England.
We suspect a complex relationship between the exposures studied here, some of which may be on the same causal pathway for early death. For example, high age and comorbidity may be rational and adequate reasons for not offering surgery. While a number of patient and treatment characteristics were strongly and independently linked with early death, these associations must be interpreted with caution and with a consideration for unmeasured confounding factors. For instance, the selection of a patient's treatment will depend on a number of factors, including some not measured here such as their own preferences or established practices within the organisation in which they are treated. 33 Furthermore, their presentation to health services depends, among other factors, on access to treatment and knowledge of cancer symptoms. Many of these variables may be linked to both risk factors and outcomes and they have not been assessed in this study. However, for any underlying confounder to explain the strong statistical associations seen in our data, they would need to have a very strong correlation with death within a year of diagnosis.
Five-year relative survival in our sample (based on life tables for London during the period 1996-2001) was 84.1%. This is similar to recent estimates from the Office for National Statistics, 34 which reports a value of 82% for women diagnosed between 2000 and 2006. Thus our cohort sample is likely to be reasonably representative of the UK population of women diagnosed with breast cancer during this period. Table 6 compares the audit data to the total registrations for female breast cancer in the North Thames region at TCR. Mean ages at diagnosis were similar throughout the study period. Likewise, the proportion of patients dying within one year of diagnosis were broadly similar, though slightly lower in the audit database (6.5% vs 7. 
Conclusions
Our findings offer detailed insights into the determinants of death in the first year after a diagnosis of breast cancer, a period shown to be important in international comparisons. As expected, early death is linked to older age and to the presence of comorbidities. Comorbidities can be addressed in the long run through general health policy, but two other determinants of early death identified by this study are potential avenues for intervention.
Firstly, the findings relating to disease severity lend empirical support to the notion that late diagnosis is a major determinant of early death. This supports the rationale for projects that focus on increasing awareness of breast symptoms and the importance of screening. Secondly, surgery is independently associated with a large reduction in the risk of early death, and older women were -independently of disease severity and comorbidity -much less likely to receive surgery. Assuming surgery is an indicator of attempts at curative treatment, there may be benefits of increased treatment activity for older women. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 
